Keyphrases
Immune-related
100%
Neutropenia
100%
Immune Checkpoint Inhibitors
100%
Confidence Interval
81%
Corticosteroids
45%
Intravenous Immunoglobulin (IVIg)
27%
Granulocyte Colony-stimulating Factor (G-CSF)
27%
Granulocytes
27%
Cyclosporine
18%
Immune-related Adverse Events
18%
Israeli
9%
Treatment Strategy
9%
Clinical Course
9%
Life-threatening
9%
Odds Ratio
9%
Clinical Factors
9%
Hyperplasia
9%
Recurrence Rate
9%
Rechallenge
9%
Bone Marrow Biopsy
9%
Median Time
9%
Hypoplasia
9%
Early Onset
9%
Lymphocyte Infiltration
9%
Existing Data
9%
PubMed Search
9%
Better Prognosis
9%
Time to Onset
9%
Cancer Center
9%
Resolution Rate
9%
Salvage Treatment
9%
Febrile Neutropenia
9%
Day Range
9%
Peripheral Component
9%
Pathologic Factors
9%
Internal Database
9%
Biochemistry, Genetics and Molecular Biology
Intravenous Immunoglobulin
100%
Immune Checkpoints
100%
Granulocyte
100%
Granulocyte Colony-Stimulating Factor
100%
Ciclosporin
66%
Maturation
33%
Lymphocyte
33%
Medline
33%
Immunology and Microbiology
Intravenous Immunoglobulin
100%
Granulocyte Colony-Stimulating Factor
100%
Granulocyte
100%
Ciclosporin
66%
Maturation
33%
Lymphocyte
33%
Lineages
33%
Medline
33%
Medicine and Dentistry
Neutropenia
100%
Immune Checkpoint Inhibitor
100%
Granulocyte Colony Stimulating Factor
27%
Granulocyte
27%
Immune-Related Adverse Events
18%
Cyclosporine
18%
Malignant Neoplasm
9%
Maturation
9%
Bone Marrow Biopsy
9%
Odds Ratio
9%
Disease Course
9%
Hyperplasia
9%
Recurrence Risk
9%
Hypoplasia
9%
Lymphocytic Infiltration
9%
Febrile Neutropenia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Neutropenia
100%
Granulocyte Colony Stimulating Factor
27%
Adverse Event
18%
Ciclosporin
18%
Malignant Neoplasm
9%
Disease Course
9%
Recurrence Risk
9%
Hyperplasia
9%
Hypoplasia
9%
Lymphocytic Infiltration
9%
Febrile Neutropenia
9%